Photo of William C. DeWolf,  FACS, MD

William C. DeWolf, FACS, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-8903
Fax: (617) 667-7292


wdewolf@caregroup.harvard.edu

William C. DeWolf, FACS, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Beth Israel Deaconess Medical Center Professor of Surgery, Surgery, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int 2014. PubMed
  • Delto JC, Kacker R, Bubley G, DeWolf WC. Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder. Clin Genitourin Cancer 2014; 12:e35-6. PubMed
  • Costa DN, Bloch BN, Yao DF, Sanda MG, Ngo L, Genega EM, Pedrosa I, DeWolf WC, Rofsky NM. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. Magn Reson Imaging 2013. PubMed
  • Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol 2012; 22:2201-10. PubMed
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185:471-6. PubMed
  • Dewolf WC. Re: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Editorial comment. J Urol 2010; 184:878. PubMed
  • Schopperle WM, Lee JM, Dewolf WC. The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cells. Biochem Biophys Res Commun 2010; 398:372-6. PubMed
  • Lee KS, Zeikus E, DeWolf WC, Rofsky NM, Pedrosa I. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol 2010; 65:185-92. PubMed
  • Olumi AF,Dewolf WC. The hybrid of basic science and clinical training for the urologic oncologit: Necessity or waste? Urol Oncol 2009; 27:205-7. PubMed
  • Pedrosa I,Sun MR,Spencer M,Genega EM,Olumi AF,Dewolf WC,Rofsky NM. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics 2008; 28:985-1003. PubMed
  • Dewolf WC. Re: are doctors examining prostates in university hospital? Eur Urol 2008; 53:1296-7. PubMed
  • Pedrosa I, Chou MT, Ngo L, H Baroni R, Genega EM, Galaburda L, DeWolf WC, Rofsky NM. MR classification of renal masses with pathologic correlation. Eur Radiol 2007; 18:365-75. PubMed
  • Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. Urology 2008; 71:47-51. PubMed
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67:9425-34. PubMed
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006; 175:1341-5; discussion 1345-6. PubMed
Hide